TRINETRA › Sectors › Healthcare
Pfizer Limited (PFIZER) — share price, P/E and fundamentals
Pfizer Limited (NSE: PFIZER) closed at ₹3,687.80 on 30 Oct 2026, -31.1% over one year, against a 52-week range of ₹3,595.00 – ₹5,446.00.
In the quarter ended 30 Jun 2026 (standalone, filed 28 Jul 2026) it reported revenue of ₹653 cr and net profit of ₹204 cr, a 31.3% net margin; revenue grew 8.3% and profit grew 6.6% year on year.
On four consecutive filed quarters its trailing P/E is 23.0; since 20 May 2025 its own P/E has ranged from 22.5 to 35.1 (median 29.7), and today's reading is higher than 1% of those 358 trading days.
From the balance sheet dated 31 Mar 2026: return on equity 19.5%, ROCE 25.9%, debt-to-equity 0.00, Piotroski F-score 6 of 9.
Against 65 Healthcare peers on NSE: Net margin higher than 100% of 63 sector peers; PBT margin higher than 100% of 63 sector peers; ROE higher than 73% of 63 sector peers.
Key figures
| Last close | ₹3,687.80 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | -8.9% / -22.1% / -31.1% |
| 52-week low – high | ₹3,595.00 – ₹5,446.00 |
| Market capitalisation | ₹16,872 cr |
| Trailing P/E | 23.0 |
| Price / book | 4.01 |
| EV / EBITDA | 15.9 |
| Earnings yield | 4.4% |
| TTM EPS | ₹160.69 |
| TTM net profit | ₹735 cr |
| Quarter revenue | ₹653 cr |
| Quarter net profit | ₹204 cr |
| Net margin | 31.3% |
| Revenue growth (YoY) | +8.3% |
| Profit growth (YoY) | +6.6% |
| Return on equity | 19.5% |
| ROCE | 25.9% |
| Debt / equity | 0.00 |
| Current ratio | 6.06 |
| Free cash flow | ₹942 cr |
| Piotroski F-score | 6 / 9 |
| Average daily turnover (50 days) | ₹9.9 cr |
Against Healthcare peers
| Metric | PFIZER | Peer median | Percentile |
|---|---|---|---|
| Net margin | 31.30 | 12.67 | 100 |
| PBT margin | 42.36 | 17.57 | 100 |
| ROE | 19.46 | 13.86 | 73 |
| ROCE | 25.91 | 16.59 | 81 |
| Debt / equity | 0.00 | 0.11 | 12 |
| Cash conversion | 1.34 | 1.25 | 57 |
| Trailing P/E | 22.95 | 43.26 | 9 |
| P/B | 4.01 | 6.02 | 24 |
Questions
What is the P/E ratio of Pfizer Limited?
Pfizer Limited's trailing P/E is 23.0, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Jun 2026. Since 20 May 2025 its P/E has ranged 22.5–35.1.
What were Pfizer Limited's latest quarterly results?
For the quarter ended 30 Jun 2026, Pfizer Limited reported revenue of ₹653 cr and net profit of ₹204 cr (standalone), filed with the exchange on 28 Jul 2026.
What is Pfizer Limited's ROE?
Return on equity is 19.5% based on the balance sheet dated 31 Mar 2026.
Does Pfizer Limited have debt?
Debt-to-equity is 0.00 on the balance sheet dated 31 Mar 2026.
What is PFIZER's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, PFIZER traded between ₹3,595.00 and ₹5,446.00.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
Source: standalone SEBI Integrated Filing for the quarter ended 30 Jun 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.